Ultromics, spun out of the University of Oxford, offers EchoGo®, an artificial-intelligence platform that turns routine cardiac ultrasounds into objective diagnostic reports. The system is trained on one of the world’s largest echocardiography datasets and validated against actual patient outcomes, enabling it to identify subtle markers of HFpEF that are frequently missed in standard workflows. EchoGo has already analyzed more than 430,000 echocardiograms and is deployed in hospitals across the United States and the United Kingdom. Clinical studies cited by the company show the software reached a diagnostic decision in 93% of patients versus 40% for traditional HFpEF risk scores, with consistent accuracy across gender, age and risk groups. Ultromics’ technology is reimbursed by public and private payers and is cleared by the U.S. FDA, underscoring its commercial readiness. Backed by multiple investors and health systems, the company aims to make early identification of heart failure a standard part of cardiac care worldwide.

Total raised

$111M

Funding rounds

5

Latest round

Series C

Latest activity

Jul 2025